Metformin Ameliorates Lipotoxic β-Cell Dysfunction through a Concentration-Dependent Dual Mechanism of Action

Area of Science:

• Endocrinology
• Metabolism
• Molecular Biology

Background:

• Chronic exposure to free fatty acids impairs pancreatic beta-cell function.
• Metformin's effects on beta-cells are not fully understood, with prior studies yielding inconsistent results.
• Investigating metformin's impact on beta-cells under lipotoxic stress is crucial.

Purpose of the Study:

• To elucidate the concentration-dependent effects of metformin on pancreatic beta-cells experiencing lipotoxicity.
• To determine the molecular pathways involved in metformin's protective action against palmitate-induced beta-cell dysfunction.

Main Methods:

• Utilized NIT-1 cells and mouse islets exposed to palmitate and treated with varying metformin concentrations (0.05 and 0.5 mM).
• Assessed cell viability, insulin secretion, ATP levels, reactive oxygen species (ROS), and Rho kinase (ROCK) activity.
• Measured AMP-activated protein kinase (AMPK) phosphorylation and mRNA levels of endoplasmic reticulum (ER) stress and NADPH oxidase (NOX) markers.

Main Results:

• Metformin demonstrated protective effects against palmitate-induced beta-cell dysfunction.
• Low-dose metformin (0.05 mM) inhibited NOX, reducing ER stress markers and ROS independently of AMPK.
• High-dose metformin (0.5 mM) inhibited ROCK activity and activated AMPK.

Conclusions:

• Metformin's therapeutic action on beta-cell lipotoxicity is concentration-dependent, involving distinct molecular pathways.
• At typical therapeutic doses, metformin likely alleviates lipotoxic beta-cell dysfunction by inhibiting oxidative and ER stress.
• Understanding these mechanisms can inform strategies for managing type 2 diabetes and related complications.